Navigation Links
Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
Date:4/20/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, April 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will present at the Alliance for Regenerative Medicine's (ARM) 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 09:40 EDT in Boston.

In addition, Dr. Ralph Kern, MD, MHSc, Chief Medical Officer & Chief Operating Officer, will participate in a panel titled "Cell Therapy Beyond Oncology: Where Does The Greatest Potential Lie?".

BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics

ARM's 5th Annual Cell & Gene Therapy Investor Day Presentation and Panel Details:


Event:     Alliance for Regenerative Medicine's Cell & Gene Therapy
Investor DayDate:      

April 27, 2017Time:       

Presentation (Mr. Lebovits): 09:40 AM EDT
Panel (Dr. Kern): 10:25 AM EDT Location:   

The State Room, 60 State Street, Boston, MA 02109

A live video webcast of the presentation will be available at: http://www.arminvestorday.com/webcast. The webcast will be posted for further viewing on the event website following the conference.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://www.arminvestorday.com for more information.

About ARM's Cell & Gene Therapy Investor Day
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTSMedia:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-arms-5th-annual-cell--gene-therapy-investor-day-april-27-in-boston-300442562.html


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
2. BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israels Chief Scientist Office
3. BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
4. BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
5. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
6. BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
7. BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
8. BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israels Office of the Chief Scientist
9. BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
10. BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
11. BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found ... latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, ... effect on men. ”The logical next step, in my estimation, was to scientifically track ...
(Date:6/20/2017)... ... June 20, 2017 , ... GigaGen ... from millions-diverse immune repertoires, announces launch of its new Surge(TM) Discovery ... PhD, CEO of GigaGen, will present on Surge at the conference. , Surge ...
(Date:6/16/2017)... Massachusetts (PRWEB) , ... June 16, 2017 , ... ... medical device compliance and commercialization, has just announced two more sessions of its ... the series will focus on the world of online templates for design control ...
(Date:6/15/2017)... ... June 15, 2017 , ... The newest exhibition ... journey through creative experimentation and interdisciplinary collaboration. Feature Creep, a solo exhibition by ... opening reception will be held at EKG, located at 3600 Market Street in ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):